A phase III trial administered atezolizumab (ICI, anti-PD-1 antibody) 1200 mg plus bevacizumab (anti-VEGF antibody) 15 mg/kg once in every 21-day cycle for 12 months to 668 high-risk HCC recurrence patients after ablation or resection [76]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.